Allergy Therapeutics Plc (AGY) Ord GBP0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Allergy Therapeutics starts dosing peanut allergy vaccine candidate
27 March 2023 15:16
(Sharecast News) - Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its 'VLP Peanut' vaccine candidate in...
-
Allergy Therapeutics confident in funding as results remain late
20 January 2023 12:33
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said in an update on Friday that it expects first-half revenue of £39.9m, making for a decrease of 18% year-on-year.
-
Allergy Therapeutics pauses production at Freeman facility
4 October 2022 14:10
(Sharecast News) - Biotechnology company Allergy Therapeutics has "proactively paused" production at the Freeman facility, part of its Worthing manufacturing site, to accelerate ongoing site...
-
Allegy Therapeutics trades 'robustly' in tough year
15 July 2022 11:58
(Sharecast News) - Allergy Therapeutics updated the market on the financial year just ended on Friday, with the phase one 'Peanut PROTECT' trial, incorporating "ground-breaking" VLP...
-
Allergy Therapeutics reports positive results from field study
25 October 2021 10:45
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive top-line results from its exploratory field study 'G309' to evaluate the efficacy and safety of its short-course...
-
Allergy Therapeutics upbeat on ex-vivo study of peanut allergy vaccine
3 August 2021 13:43
(Sharecast News) - Pharmaceutical biotechnology company Allergy Therapeutics announced positive primary results from an ex-vivo biomarker study on Tuesday, evaluating its novel virus-like particle...
-
Allergy Therapeutics FY profits seen 'well ahead' of expectations
24 June 2021 08:07
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Thursday that full-year operating profits were expected to be "well ahead" of market expectations thanks to...
-
Allergy Therapeutics completes treatment in G309 field study
6 May 2021 15:34
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and...
Company announcements Announcements
-
Director Resignation
3 April 2024 07:00
Allergy Therapeutics
-
Interim Results for six months ended 31 Dec 2023
27 March 2024 07:00
Allergy Therapeutics
-
Update on funding
27 March 2024 07:00
Allergy Therapeutics
-
VLP Peanut PROTECT Trial Update
12 March 2024 08:59
Allergy Therapeutics
-
Appointment of Shaun Furlong to Board of Directors
11 March 2024 07:00
Allergy Therapeutics
-
Result of AGM
8 March 2024 13:49
Allergy Therapeutics
-
Half-Year Trading Update 2024
14 February 2024 07:00
Allergy Therapeutics
-
Notice of 2023 Annual General Meeting
9 February 2024 15:07
Allergy Therapeutics
-
Restoration - Allergy Therapeutics plc
30 January 2024 07:30
Allergy Therapeutics
-
Publication of Annual Report and Accounts 2023
30 January 2024 07:00
Allergy Therapeutics
-
Total Voting Rights
4 January 2024 12:29
Allergy Therapeutics
-
Suspension - Allergy Therapeutics plc
2 January 2024 07:30
Allergy Therapeutics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.